Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Pharmaceutical compositions comprising nilotinib or its salt|
|Abstract:||A pharmaceutical composition, especially capsules, comprising granules containing nilotinib or a salt thereof with at least one pharmaceutically acceptable excipient. The granules may be produced by a wet granulation process.|
|Inventor(s):||Bruneau; Nathalie (Cran-Gevrier, FR)|
|Assignee:||Novartis AG (Basel, CH)|
1. A pharmaceutical composition, in the form of a capsule comprising: a granule comprising a therapeutic compound in an intimate mixture with at least one pharmaceutically
acceptable excipient, wherein said therapeutic compound is a monohydrochloride salt of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imida- zol-1-yl)-3-(trifluoromethyl)phenyl]benzamide of formula: ##STR00003## as a monohydrate,
wherein said granule further comprises a surfactant and a lubricant, said surfactant is in a concentration from 0 to 1% by weight of said pharmaceutical composition and the concentration of said lubricant does not exceed 1% by weight of the
2. The pharmaceutical composition of claim 1, wherein said lubricant is magnesium stearate.
3. The pharmaceutical composition of claim 2, wherein said surfactant is a poloxamer.
4. The pharmaceutical composition of claim 3, wherein said poloxamer is poloxamer 188.
5. The pharmaceutical composition of claim 1, wherein said said therapeutic compound and excipients are combined to form granules, which are further dried to form a powder blend of granules.
6. A pharmaceutical composition, in the form of a capsule comprising: 55.2% by weight of monohydrochloride salt of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imida- zol-1-yl)-3-(trifluoromethyl)phenyl]benzamide of formula: ##STR00004## as a monohydrate; 0.8% by weight of a surfactant; 19.6% by weight of a diluent; 4% by weight of a disintegrant; and an external phase further comprising: 19.4% by weight of a diluent; 0.5% by weight of a glidant; and 0.5% by weight of a lubricant and water, wherein water is used as a granulation liquid.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.